|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
Gains by Cephalon and Genzyme help boost the Amex biotech index. Amylin shares fall 1.7% after talks about pancreatitis and diabetes drug Byetta.
Pfizer will pay $225 million up front to gain worldwide marketing rights to Dimebon.
Multiple sclerosis treatment Tysabri may cause a deadly brain infection whether used alone or with other treatments.
Large shareholders are clamoring for change at these companies; their bets may be worth piggybacking.
The company was the best performer on the Amex Pharmaceuticals Index Friday.
Why Titan Pharma needs a development partner. And disparate outlooks for Gilead, Vanda and YM BioSciences.
Bank of America is among the most-searched stocks on TheStreet.com. Here's what Cramer had to say about it recently.
These heavily shorted stocks have the potential to move higher in the coming days.
The market had risen earlier after the Labor Department's jobs report came in better than expected. Simon Constable reviews the session in The Real Story (above).
A conference call does little to allay investor fears that more incidents of the serious brain infection could emerge in Tysabri patients.
Revaluing a severely beaten Elan. And wanted: Your votes on best biotech CEO.
Two confirmed cases of PML in patients treated with Tysabri sends both stocks spiraling downward.
The sector is trading higher on today's buyout bid. One analyst offers a list of who else could tie the knot in the drug and biotech space.
Elan and Wyeth sink on study results of Alzheimer's treatment bapineuzumab.
The stocks sell off after the presentation of underwhelming and inconclusive study results of bapineuzumab. Let's break it down.
The drug stocks tumble on weak results from a much-anticipated phase II study of bapineuzumab.
Elan slips despite a narrowed second-quarter loss and strong Tysabri sales.
The biotech beats Wall Street estimates by 7 cents a share as sales of Tysabri and Rituxan surge.
Phase II study results show Dimebon improves the mental status of Huntington's disease patients, but a clerical error in previous regulatory filings misstated the study's endpoints.
The phase II study results show the experimental drug improves the mental status of patients with Huntington's disease.
Here are the data and regulatory decisions that are likely to be the biggest catalysts from July to December.
Here are some of the stocks the crew has been talking about lately.
Confessions of a former Panacostal; weighing Indevus' chances after its latest FDA blow; and more Elan.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.